Aquestive Therapeutics To Present Anaphylm Sublingual Film Pharmacokinetic And Pharmacodynamic Data At 2024 AAAAI Annual Meeting
Portfolio Pulse from Benzinga Newsdesk
Aquestive Therapeutics announced it will present data at the 2024 AAAAI Annual Meeting showing its Anaphylm Sublingual Film, a non-invasive epinephrine delivery method, has comparable efficacy to traditional autoinjectors like EpiPen and Auvi-Q. A Phase 3 study of Anaphylm is in progress, with results expected in Q1 2024.
February 15, 2024 | 1:08 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Aquestive Therapeutics is set to present promising data on Anaphylm Sublingual Film, indicating its potential as the first non-invasive, orally delivered epinephrine product.
The positive clinical trial results and the innovative nature of Anaphylm Sublingual Film position Aquestive Therapeutics favorably in the market. The anticipation of Phase 3 results could generate investor interest and potentially increase stock value in the short term, especially considering the novelty and potential market demand for a non-invasive epinephrine delivery system.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100